[8-K] Oragenics Inc. Reports Material Event

Rhea-AI Filing Summary

Oragenics, Inc. filed a Current Report on Form 8-K dated August 11, 2025 stating the company issued a press release updating shareholders on developments in the second quarter of 2025 and shortly thereafter. The filing expressly attaches that press release as Exhibit 99.1 and includes the cover page Interactive Data File as Exhibit 104.

The 8-K lists Oragenics' state of incorporation as Florida, its trading symbol OGEN on NYSE American, the principal executive office address and phone number, and is signed by CEO Janet Huffman. The body of the filing notifies investors of the press release but does not include additional financial or operational detail beyond the exhibits referenced.

Insights

Securities Analyst

TL;DR The 8-K notifies the market of a shareholder update via press release; substantive details are contained in Exhibit 99.1.

The filing meets disclosure protocol by reporting issuance of a press release and incorporating that release by reference. Because the 8-K itself provides no financial figures or operational metrics, the document alone does not allow assessment of earnings, revenue, or cash position changes. Investors must review Exhibit 99.1 for material facts that could affect valuation or near-term expectations.

Corporate Governance Expert

TL;DR The company filed a timely Form 8-K, included required exhibits, and the filing is signed by the CEO.

The submission documents standard corporate disclosure practices: the press release is attached as Exhibit 99.1, an Inline XBRL cover page is included as Exhibit 104, and the Form 8-K bears the signature of CEO Janet Huffman. From a governance and compliance perspective the form is complete; however, the filing defers substantive content to the attached press release rather than presenting details in the 8-K text.

false 0001174940 0001174940 2025-08-11 2025-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

Date of Report: August 11, 2025

(Date of earliest event reported)

Oragenics, Inc.

(Exact name of registrant as specified in its charter)

FL		001-32188		59-3410522
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

1990 Main Street Suite 750 Sarasota, FL		34236
(Address of principal executive offices)		(Zip Code)

813-286-7900

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		OGEN		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 8.01. OTHER INFORMATION.

On August 11 2025, Oragenics, Inc. (the “Company”) issued a press release updating the Company’s shareholders on recent Company developments that have occurred in the second quarter of 2025 and shortly thereafter. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release Dated, August 11, 2025.
104		Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL)

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 11^th day of August 2025.

	ORAGENICS, INC. (Registrant)
	BY:	/s/ Janet Huffman
		Janet Huffman Chief Executive Officer